MedTrace Logo

Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients

NCT06104423 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 266

Last updated 2025-04-24

Study results available
· View outcomes & findings →

Summary

Open-label, inteRventional clinical Trial to assess EffIcacy and safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients.

Conditions

Interventions

DRUG

Nebivolol 5 mg

1 tablet of study medication (5mg) to be administered orally according to instructions of Investigator.

DRUG

Ramipril 2.5/5/10 mg

1 tablet of study medication (2.5mg or 5mg or 10mg) to be administered orally according to instructions of Investigator.

Sponsors & Collaborators

  • Menarini International Operations Luxembourg SA

    lead INDUSTRY

Principal Investigators

  • Giovambattista Desideri, Prof · University of Roma La Sapienza

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-02
Primary Completion
2024-02-19
Completion
2024-02-19

Countries

  • Hungary

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06104423 on ClinicalTrials.gov